Treatment of Drug Eluting Stents Restenosis. Single Centre Experience

摘要

The introduction of drug eluting stents (DES) allowed to reduce the restenosis rates. However, the optimal treatment of DES restenosis is an unresolved clinical problem. We performed a single centre retrospective analysis of DES restenosis in a cath lab of a tertiary hospital. 90 patients, who presented 123 lesions, were included between Jun'03 to April '07. 77% patients presented single lesion and 32% multiple restenotic lesions. The median time to restenosis was 10.5 +- 7 months. The drug of the restenotic stents was paclitaxel in 64%, sirolimus in 16%, tacrolimus in 7% and zotarolimus in 11%. 12% of the lesions were not treated, 3% recieved by-pass surgery and 8% were treated with simple PTCA. The remaining 77% received a new stent (DES in 99.4%). Finally, 126 new stents were implanted (1.7 stents/patient; 1.2 stents/lesion). The preferable treatment for a DES restenosis in our centre was a new DES (77% of lesions). 44% of them received a different drug in the new procedure.